637 - Infant hospitalizations and ICU Admissions for Bronchiolitis and RSV-BRONCHIOLITIS are at historic highs during 2022 early seasonal disease: results from Four US health systems
Saturday, April 29, 2023
3:30 PM – 6:00 PM ET
Poster Number: 637 Publication Number: 637.226
Charles T. Wood, Duke University, Durham, NC, United States; Emmanuel Walter, Duke Human Vaccine Institute, Durham, NC, United States; Zachary Wolf, Clinetic, Durham, NC, United States; Emory Waddell, Clinetic, Raleigh, NC, United States; Sonia Budhecha, Renown Children's Hospital Renown Regional Medical Center, Reno, NV, United States; Claudia M. Espinosa, University of Florida, Tampa, FL, United States; Maria Elizabeth Enriquez-Bruce, University of South Florida, Tampa, FL, United States; Joseph Domachowske, SUNY Upstate Medical University, Syracuse, NY, United States; Danielle Daniels, Upstate Golisano Children's Hospital, Pennellville, NY, United States; Mina Suh, EpidStrategies, Mission Viejo, CA, United States; Jon Fryzek, EpidStrategies, Rockville, MD, United States; Christopher B. Nelson, Sanofi, Swiftwater, PA, United States
Pediatric Infectious Diseases Fellow Upstate Golisano Children's Hospital Pennellville, New York, United States
Background: In the US, respiratory syncytial virus (RSV) is the leading cause of infant hospitalization and lower respiratory tract infections including bronchiolitis. Surveillance shows that since the start of the COVID-19 pandemic in March 2020, bronchiolitis and RSV-bronchiolitis epidemiology among US infants has been changing. Objective: To assess trends in hospitalizations and ICU admissions for infant bronchiolitis and RSV-bronchiolitis since the start of the COVID-19 pandemic, across four US health systems. Design/Methods: We assessed electronic health record (EHR) ICD-10-CM and laboratory testing data from the Duke University Health System, Renown Health System, USF Health/Tampa General Hospital, and SUNY Upstate Medical University from October 2015 to November 2022. Results: During the recent early 2022 RSV season, infant hospitalizations (Figures 1a, 1b), and ICU admissions and mechanical ventilation use (Figures 2a, 2b) for bronchiolitis and RSV-bronchiolitis have reached the highest levels since the start of our surveillance period in 2015.
Conclusion(s): The recent 2022 early bronchiolitis and RSV-bronchiolitis season has resulted in historically high levels of severe disease among infants. Continued monitoring of RSV-bronchiolitis trends is needed.
